Pharmacotherapy for Stimulant Use Disorder: Appropriate When Nothing Is FDA-Approved?
A patient has made real progress in behavioral treatment for methamphetamine use disorder and then plateaued. No medication holds FDA approval for this disorder — but one off-label combination has real randomized trial evidence behind it.
D.L. raised the subject of medication for the first time in four months at today's visit — a small shift his counselor, present for the conversation, said afterward she was glad to see. “Is there a pill for this?” he finally asked, almost apologetically, as though he'd been holding the question back on purpose. He is forty-three, and used to run sound for a regional touring band before methamphetamine use cost him that job two years ago, along with the apartment that came with steady income. He still keeps a mixing board in storage, a detail he brings up often, and says getting back to work in some form of audio, even part-time, is what he's actually aiming for once he feels stable enough to try.
He has been in outpatient treatment for four months, attending group counseling three times weekly, and has reduced his use substantially but not stopped — roughly six days of use per month currently, down from near-daily use at his worst. He has engaged consistently with contingency management, the clinic's incentive-based behavioral program, and credits it directly with the reduction he's achieved so far. But he has plateaued over the past six weeks despite continued participation, and both he and his counselor feel he's reached the edge of what behavioral treatment alone is accomplishing right now. He has no other significant medical history, no cardiac disease, and normal blood pressure. He'd heard from another group member that some doctors prescribe something for methamphetamine cravings, and was visibly disappointed to learn there is no FDA-approved medication for stimulant use disorder at all.
Nothing is FDA-approved. That isn't the same as nothing works.
I'd offer the off-label combination of extended-release naltrexone plus extended-release bupropion. The ADAPT-2 trial — a randomized, placebo-controlled NIDA network study — found this combination produced a real, statistically significant treatment response, 13.6% versus 2.5% on placebo. Neither drug carries an FDA approval for this specific indication, but the trial result is genuine, and he's plateaued on behavioral treatment alone despite real, consistent effort.
I don't dispute the trial data, but I want to name a real risk in how we introduce this: his reduction so far came from consistent contingency management engagement, and if a medication arrives framed as "the next step," it could subtly signal that the behavioral work is now secondary or that a pharmacologic fix has taken over. That program is still what's actually working for him.
I take that seriously, but I don't think offering an evidence-based medication necessarily has to carry that message — it depends entirely on how explicitly we frame it as additive rather than as a replacement for what he's already doing.
Then let's make that framing explicit and direct, not assumed: tell him plainly that contingency management stays exactly as it is, unchanged and just as important, and that the medication is one additional tool sitting alongside it, not instead of it. Given his plateau and his own request, I think he's ready to hear that distinction clearly.
Agreed: naltrexone-bupropion started as an explicitly framed augmentation, with contingency management continuing unchanged and its ongoing importance stated to him directly.
Not agreed: whether this combination should be offered proactively to every patient who plateaus on behavioral treatment for stimulant use disorder, or reserved for patients who specifically request a medication option the way D.L. did. The addiction psychiatrist favors proactively raising it given the trial data; the behavioral health specialist prefers it remain patient-initiated to keep the behavioral program's primacy clear by default.